Category: clinical study retractions

Psychologist Jens Forster settles case by agreeing to 2 retractions

forster-j-a
Jens Förster

Following questions about the veracity of multiple papers by his former employer, high-profile social psychologist Jens Förster has agreed to retract two papers as part of a deal with the German Society for Psychology (DGPs).

Last year, Förster had a paper retracted at the request of his former employer, the University of Amsterdam (UvA). In May, an investigation commissioned by UvA found that many of his experiments looked “too good to be true,” and eight papers showed strong signs of “low veracity.”

Just two of those papers are acknowledged in the settlement of a case by the DGPs against Förster, who currently works at Ruhr University Bochum. Here’s a translation of a notice from the DGPs from One Hour Translation:

Continue reading Psychologist Jens Forster settles case by agreeing to 2 retractions

When a paper is retracted, so is its previous correction–sometimes

1-s2.0-S0968089612X0018X-cov150hSometimes, the path to correcting the scientific record takes a few turns. In the case of a paper about a new cancer compound, authorship issues led to a correction and, ultimately, a retraction — along with a double-back to retract the earlier correction.

We reported on the first part of the story back in January: A 2011 paper that described a novel compound that could work as a drug for the side effects of chemotherapy was corrected in 2012 to add additional authors. But once the authors realized their supposedly novel compound had actually been synthesized by another author, they decided to retract the paper from Bioorganic and Medicinal Chemistry earlier this year, concluding “these facts made the paper inappropriate and unfaithful.”

Apparently, around the same time, the authors decided to retract the earlier correction, as well:

Continue reading When a paper is retracted, so is its previous correction–sometimes

Intellectual property issues sink cancer paper in JACS

176 spine minimum. full size. Editor: Lingling JEM: Leslie RTP: Michael ReidThe authors of a paper on a mechanism for potential cancer therapies are retracting it after realizing they published some proprietary findings “without permission and agreement from St. Jude Children’s Research Hospital.”

According to the retraction note in Journal of the American Chemical Society, the authors included an X-ray crystal structure and data that were gathered at St. Jude’s and considered the hospital’s intellectual property. On the paper, the last author, Zhengding Su, listed an affiliation at St. Jude and Hubei University of Technology in China, along with Amersino Biodevelop Inc., based in Waterloo, Canada.

Here’s the note for “Efficient Reactivation of p53 in Cancer Cells by a Dual MdmX/Mdm2 Inhibitor:”  Continue reading Intellectual property issues sink cancer paper in JACS

Food article pulled when authors can’t serve up data

homeHeaderLogoImage_en_USAn article about a dietary plan to help people lose weight has been retracted after other researchers raised concerns, and the authors failed to provide the data that supported their findings.

The retraction is accompanied by a Letter to the Editor by a group of outside researchers — including David Allison at the University of Alabama at Birmingham — who noticed “several substantial issues with data and calculations.” For instance, before the experiment even started, the two groups had very different weights: The control group averaged 96.5 kg, and the test group 91 kg. According to the letter, that difference is striking: Continue reading Food article pulled when authors can’t serve up data

St. Jude investigation finds faked data in brain tumor paper

S00396060An investigation at St. Jude Children’s Hospital into “irregularities” in a figure featured in a neuroblastoma paper has concluded that the image was fabricated. The paper, published in Surgery in 2012, was retracted on Friday.

Here’s the full retraction notice for “Liposome-encapsulated curcumin suppresses neuroblastoma growth through nuclear factor-kappa B inhibition:”

Continue reading St. Jude investigation finds faked data in brain tumor paper

Heart researcher who faked patient data gets third retraction

Screen Shot 2015-11-06 at 6.38.09 PMA heart researcher has notched her third retraction, a small 2006 trial in Annals of Internal Medicine which seemed to show that a blood pressure drug could help people with artery disease walk further with less pain.

Earlier this year, Anna Ahimastos, formerly a researcher at Baker IDI Heart and Diabetes Institute in Melbourne, lost a larger clinical trial in JAMA and a subanalysis in Circulation Research after it was discovered she’d fabricated patient records. As principle investigator Bronwyn Kingwell told us in September:

Specifically, records were fabricated for trial participants that did not exist.

Now, following an investigation by the institute, her co-authors are proactively retracting papers, with more to come. The Annals of Internal Medicine paper, “Ramipril Markedly Improves Walking Ability in Patients With Peripheral Arterial Disease,” is being pulled due to an “inability to adequately validate primary data sources.” According to the note, Ahimastos “maintains the integrity of the data and validity of reported results:”

Continue reading Heart researcher who faked patient data gets third retraction

Study claiming dramatically higher rates of male military sexual trauma is retracted

psychological servicesA study that found a 15-fold increase in the rate of sexual trauma among men in the U.S. military — and sparked suggestions of “an epidemic of male-on-male sex crimes” in the military among conservative media outlets — has been retracted because of a flaw in the analysis.

The study, published just last week, appeared in Psychological Services, an American Psychological Association (APA) journal. In an announcement Sunday titled “American Psychological Association Retracts Article Positing Excessively High Rates of Sexual Trauma Among Military Men,” the APA said that “Scholars raised valid concerns regarding the design and statistical analysis which compromise the findings.” Here’s the text: Continue reading Study claiming dramatically higher rates of male military sexual trauma is retracted

Got the blues? You can still see blue: Popular paper on sadness, color perception retracted

home_coverA paper published in August that caught the media’s eye for concluding that feeling sad influences how you see colors has been retracted, after the authors identified problems that undermined their findings.

The authors explain the problems in a detailed retraction note released today by Psychological Science. They note that they found sadness influenced how people see blues and yellows but not reds and greens, but they needed to compare those findings to each other in order to prove the validity of the conclusion. And once they performed that additional test, the conclusion no longer held up.

In the retraction note for “Sadness impairs color perception,” the editor reinforces that there was no foul play:

Continue reading Got the blues? You can still see blue: Popular paper on sadness, color perception retracted

Mega-correction to several images in gastric cancer study

20.cover

A journal has issued a rather large correction — what we call “mega-correction” — to a 2014 paper on a gastric cancer biomarker that fixes problems with several of the study’s figures.

The authors write that despite the corrections, “the results and conclusions put forth in the article remain unchanged.”

The paper, “TMEFF2 Deregulation Contributes to Gastric Carcinogenesis and Indicates Poor Survival Outcome” explored the role of TMEFF2 in gastric cancer. The researchers found that the protein acts as a tumor suppressor, and low levels can indicate the presence of cancerous cells.

Here’s the full correction notice, published by Clinical Cancer Research in August:

Continue reading Mega-correction to several images in gastric cancer study

University finds “preponderance of evidence” of misconduct by child psychiatrist

JPN39_2_CoverAn investigation at the University of Illinois at Chicago has found “a preponderance of evidence” that a psychiatrist who has received millions of dollars in federal funding has committed misconduct.

One paper co-authored by Mani Pavuluri, the director of the Pediatric Mood Disorders Program, has been officially retracted so far, from the Journal of Psychiatry & Neuroscience. UIC has requested that two others be retracted as well. None of the child participants in the three papers received medication as part of the research, but the Journal of Psychiatry & Neuroscience paper was pulled after the investigation found that Pavuluri had misrepresented how much medication some children had taken outside of the study.

On Tuesday, after we’d learned of the first retraction, Pavuluri told Retraction Watch that she didn’t “want mountains made out of molehills,” but admitted to “a bit of an [Institutional Review Board] infraction.”

The retraction note from the Journal of Psychiatry & Neuroscience lays the blame squarely on Pavuluri’s shoulders:

Continue reading University finds “preponderance of evidence” of misconduct by child psychiatrist